Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, and BioSight Ltd., a pharmaceutical company developing therapeutics for hematological malignancies and disorders, entered into a definitive merger agreement pursuant to which Ayala will combine with Biosight in an all-stock transaction. The combined company will operate under the name Ayala Pharmaceuticals, Inc. The company will work to advance a portfolio of oncology assets, with a primary focus on Ayala’s AL102, a once-daily, p...